Copper peptide binds copper ions by forming a stable complex, where it utilises specific nitrogen atoms to hold the copper ion in an ordered and controlled structure. In biochemical studies, this process occurs in a 1:1 ratio, meaning one peptide molecule binds one copper ion (Cu²⁺) to form a complex known as GHK-Cu.
At the molecular level, this binding involves several points of connection, referred to as coordination sites. The copper ion is held in place by nitrogen atoms originating from different parts of the peptide. These include the amino group of glycine (one of the amino acids), the nitrogen atom from the peptide bond between glycine and histidine, and the nitrogen atom from histidine's imidazole ring (a metal-binding structure). The fourth position is typically occupied by a weakly bound ligand, such as a water molecule or another small compound. Together, these elements form a stable geometrical structure, often described as square planar, which keeps the copper ion in the correct position.
Laboratory measurements show that this binding is very strong under near-physiological conditions. It is described by stability constants, which indicate how strongly two molecules remain bound together. In this case, these values confirm that copper remains tightly bound to the peptide and does not exist in a free form. Advanced techniques such as UV-Vis spectroscopy, circular dichroism, and electron paramagnetic resonance are used to confirm this structure. These methods allow for the precise determination of the copper's coordination mode and demonstrate that it can exist in slightly different binding states depending on the environment.
The binding process is not completely rigid. It exhibits some flexibility and can adapt to the presence of other molecules. For example, compounds containing imidazole groups or molecules such as urocanic acid can interact with the complex. This can lead to the formation of more complex structures, known as ternary complexes, which further stabilise the copper without releasing it. This flexibility demonstrates that the copper peptide can bind copper safely while adapting to different biochemical conditions.
This mechanism is significant because it allows for the control of copper's behaviour in the body. Free copper ions can cause undesirable chemical reactions, particularly those leading to oxidative stress. However, when bound to copper peptides, their activity is regulated and directed in a more controlled and biologically useful manner.
Copper peptide used in research conditions is available through suppliers such as SemaxPolska. It should be noted that copper-binding properties have been observed under controlled laboratory conditions and do not directly confirm effects in the human body without further research.
What is the role of copper peptide in copper metabolism according to research?
Research suggests that copper peptide acts as both a carrier and regulator of copper ions, helping to move them around the body in a controlled and biologically safe manner. Instead of existing in a free form, which can be highly reactive and potentially harmful, copper binds to the peptide, allowing it to be transported and utilised within biological systems.
In laboratory and cell research, copper peptide is often described as a copper delivery system. It can introduce copper into cells while controlling its activity and limiting its toxicity. The complex maintains copper in the Cu(II) state, which is a stable oxidation state, and restricts its involvement in uncontrolled chemical reactions known as redox reactions. These reactions can lead to the formation of harmful molecules, so controlling them helps protect cells from damage. This allows copper to participate in important processes, such as enzyme activity and cellular regulation, without causing oxidative stress.
One of the proposed mechanisms involves copper chaperones, such as Atox1 and CCS. These are specialised transport proteins that direct copper to specific locations within the cell, including the cell nucleus, where gene activity is regulated. Copper peptide can support this system by providing copper in a readily usable form for these proteins. This creates a link between copper metabolism, gene regulation, and general cell signalling.
Additionally, copper peptide is linked to changes in biological pathways associated with tissue growth and repair. Studies have shown elevated levels of factors such as VEGF (involved in blood vessel formation), BDNF (linked to brain function), and BMP-2 (important for tissue development) in systems where copper peptide is present. These effects are likely related to copper availability influencing signalling pathways, rather than the peptide directly binding to receptors.
Copper peptide can also help maintain copper balance in the body by acting as a buffer. This means it can bind excess copper and limit its harmful effects. In experimental models, such as studies on zebrafish exposed to high copper levels, copper peptide reduced toxic effects, such as cardiac arrhythmias. This supports the hypothesis that it can regulate copper levels and limit damage under conditions of excess. It should be emphasised that the results presented are based on experimental models, and the exact role of copper peptide in human copper metabolism is still being investigated and has not been fully determined.
Peptydy miedziowe różnią się od wolnych jonów miedzi w układach biologicznych pod względem struktury, stabilności, sposobu wchłaniania i funkcji. Peptydy miedziowe to małe cząsteczki, które zawierają aminokwasy i jon miedzi. Mają one bardziej specyficzny sposób interakcji z komórkami i są mniej podatne na działania toksyczne niż wolne jony miedzi. Wolne jony miedzi są bardziej reaktywne i mogą być korzystne lub toksyczne w zależności od stężenia i kontekstu komórkowego.
Copper peptides differ from free copper ions primarily in their stability, reactivity, and the degree of biological control. Free copper ions are highly reactive and can participate in chemical reactions that lead to the formation of reactive oxygen species (ROS), which are harmful to cells. In contrast, when copper is bound to a copper peptide, it is in a stable structure that limits such uncontrolled reactions.
In its free state, copper can readily transition between different oxidation states. This enables it to initiate reactions leading to oxidative stress, which can damage proteins, lipids, and DNA. Because of this risk, the body tightly controls copper levels, and free copper is rarely found in an unbound form under physiological conditions.
Copper peptide modifies this behaviour by strongly binding copper and limiting its reactivity. In this form, the potentially harmful activity of copper is controlled, while still allowing its participation in beneficial biological processes. This means that copper can be safely transported, stored, and utilised without damaging cells.
Another significant difference concerns the availability of copper for cells. Free copper ions do not enter cells in a controlled or efficient manner. However, copper peptide supports the transport of copper into cells. it acts as a carrier, delivering copper to specific intracellular pathways where it can be utilised by enzymes or passed to transport proteins called chaperones.
These differences are also apparent in experimental studies. For example, in studies on zebrafish exposed to high concentrations of copper, free copper caused negative effects, such as cardiac dysfunction and irregular rhythm. In the presence of the copper peptide, these effects were limited. This demonstrates that the copper peptide complex alters how copper acts in biological systems.
Additionally, copper bound to a copper peptide can form more ordered structures with other molecules, referred to as coordination complexes. These may involve interactions with compounds such as urocanic acid or molecules containing imidazole groups. Such ordered interactions further control copper's activity compared to its free ionic form. It should be emphasised that the described differences between free copper and copper bound to a peptide result from experimental studies and do not constitute direct confirmation of clinical effects in humans.
Has copper peptide been studied in the context of ceruloplasmin and copper transport?
Direct studies linking copper peptides with ceruloplasmin are limited. However, broader analyses of copper transport within the body provide context to better understand its potential role. Ceruloplasmin is the primary blood protein responsible for copper transport, keeping it in a stable form and preventing its harmful effects.
Copper peptide shows some functional similarities to ceruloplasmin, as both bind copper stably and limit its reactivity. However, there are distinct differences. Copper peptide is a much smaller molecule and its action is more local, meaning it likely functions at the tissue or cellular level, rather than systemically throughout the bloodstream, as is the case with ceruloplasmin.
Research shows that copper peptide strongly binds copper and forms stable complexes under physiological conditions. These complexes can interact with other molecules and participate in local copper exchange processes. While ceruloplasmin is responsible for copper transport in the blood, copper peptide may support more precise delivery and distribution of copper in specific tissues or cells.
There is also data indicating that copper peptide interacts with intracellular copper transport systems. Proteins referred to as copper chaperones, such as Atox1 and CCS, are responsible for directing copper to different areas of the cell, including the nucleus, where gene activity is regulated. Copper peptide may act as a source of copper for these systems, supporting its utilisation within cells alongside larger transport proteins such as ceruloplasmin.
Additionally, copper peptide can form more complex structures with other molecules, referred to as ternary complexes. For instance, it may interact with compounds such as urocanic acid. These types of interactions suggest the involvement of copper peptide in local copper chemistry, distinguishing it from the broad transport performed by ceruloplasmin. Such activity may occur in specific environments, like the skin or potentially neural tissue, indicating a more targeted function.
Copper peptide used in research conditions is available through suppliers such as SemaxPolska. It should be emphasised that the relationship between copper peptide and known copper transport systems is still under investigation and has not yet been definitively confirmed as a physiological mechanism in humans.
References
- Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2012). The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative medicine and cellular longevity, 2012, 324832. https://doi.org/10.1155/2012/324832 https://pmc.ncbi.nlm.nih.gov/articles/PMC3359723/
- Mehr, A., Henneberg, F., Chari, A., Görlich, D., & Huyton, T. (2020). The copper(II)-binding tripeptide GHK, a valuable crystallisation and phasing tag for macromolecular crystallography. Acta crystallographica. Section D, Structural biology, 76(Pt 12), 1222–1232. https://doi.org/10.1107/S2059798320013741 https://pmc.ncbi.nlm.nih.gov/articles/PMC7709198/
- Ufnalska, I., Drew, S. C., Zhukov, I., Szutkowski, K., Wawrzyniak, U. E., Wróblewski, W., Frączyk, T., & Bal, W. (2021). Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione: A Handy Chelate for Biological Cu(II) Reduction. Inorganic chemistry, 60(23), 18048–18057. https://doi.org/10.1021/acs.inorgchem.1c02669 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653159/
- Bossak-Ahmad, K., Wiśniewska, M. D., Bal, W., Drew, S. C., & Frączyk, T. (2020). Ternary Cu(II) Complex with GHK Peptide and cisUrocanic Acid as a Potential Physiologically Functional Copper Chelate. International journal of molecular sciences, 21(17), 6190. https://doi.org/10.3390/ijms21176190 https://pmc.ncbi.nlm.nih.gov/articles/PMC7503498/
- Greco, V., Lanza, V., Tomasello, B., Naletova, I., Cairns, W. R. L., Sciuto, S., & Rizzarelli, E. (2025). Copper Complexes with New Glycyl-l-histidyl-l-lysine-Hyaluronan Conjugates Show Antioxidant Properties and Osteogenic and Angiogenic Synergistic Effects. Bioconjugate chemistry, 36(4), 662–675. https://doi.org/10.1021/acs.bioconjchem.4c00545 https://pubmed.ncbi.nlm.nih.gov/40123442/
- Hsiao, C. D., Wu, H. H., Malhotra, N., Liu, Y. C., Wu, Y. H., Lin, Y. N., Saputra, F., Santoso, F., & Chen, K. H. (2020). Expression and Purification of Recombinant GHK Tripeptides Are Able to Protect against Acute Cardiotoxicity from Exposure to Waterborne-Copper in Zebrafish. Biomolecules, 10(9), 1202. https://doi.org/10.3390/biom10091202 https://pmc.ncbi.nlm.nih.gov/articles/PMC7564529/